Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.

Accueil
Investir
Actions
Etats-Unis
NASDAQ
Roivant Sciences Ltd (ROIV)
Roivant Sciences Ltd (ROIV) Actualités

Roivant Sciences Ltd (ROIV)

28,41

-0,64

(-2,20%)

Fermé 11 Juin 10:00PM

27,847

-0,563

(-1,98%)

Après les heures de négociation: 1:59AM

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update

IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in...

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026

BASEL, Switzerland and LONDON and NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today...

Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)

Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied...

New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis

The results of the Phase 3 VALOR trial were published in the New England Journal of Medicine, underscoring the practice-changing potential of...

Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna

Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a...

Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis

FDA assigns PDUFA target action date in the third quarter of calendar year 2026 with launch expected at the end of September 2026Priority Review...

Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025

Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point...

Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026

DURHAM, N.C. and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that...

Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026

BASEL, Switzerland and LONDON and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today...

Roivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor Day

Roivant enters new phase of corporate journey with 3+ launches, 4+ NDA/BLA filings, 8+ pivotal and 3...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Roivant Sciences

Pure Energy Minerals

S&P ASX 200 Consumer Sta...

Babylon Pump and Power

Slave Lake Zinc

Yieldmax Xom Option Inco...

On Track Innovations

Bluestone Resources

Delayed Upgrade Clock

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

ADVFN

Vous avez déjà un compte? Connexion

Vous n'avez pas de compte ? Inscription

En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.